Clinical research
The experimental drug, if approved, will compete with GlaxoSmithKline’s Benlysta, which is the only new drug approved for lupus in the last 60 years.
In its announcement, Solid Biosciences said a patient in its second cohort who was dosed in October experienced a serious adverse event that was deemed related to the drug.
ACR Annual Meeting: Janssen’s Tremfya Nails Primary Endpoints in 24-Week Psoriatic Arthritis Studies
Both DISCOVER 1 and DISCOVER 2 are evaluating Tremfya in adults with active psoriatic arthritis.
The drug failed to meet the primary endpoints of progression-free survival and overall response rate.
A clinical Phase II safety and efficacy trial is planned for 2020 for the treatment of influenza, an indication with a very high unmet medical need
It was a busy week for clinical trial updates for the first week of November. Here’s a look.
AR101 is an investigational, peanut-derived, biologic drug candidate for oral immunotherapy in patients with peanut allergy. It delivers a daily dose of peanut protein with a consistent protein profile.
The trial demonstrated that patients receiving esaxerenone has a significantly higher Urine Albumin-to-Creatinine Ratio (UACR) of 22.1% compared to 4.0% on placebo.
Martinsried/ Munich Medigene AG announces that immune monitoring data during the first year of treatment from the ongoing Phase I / II clinical trial with Medigene’s DC vaccine for the treatment of acute myeloid leukemia will be presented at the upcoming ASH Annual Meeting taking place 7 - 10 December 2019 in Orlando, Florida, USA.
Esperion announced that pooled analyses from four Phase 3 clinical trials of bempedoic acid will be presented at the American Heart Association Scientific Sessions in Philadelphia on Sunday, November 17, 2019.
PRESS RELEASES